Pharmaceuticals, Biotechnology and Life Sciences
A UK-based private clinical-stage biotechnology company developing Narrow Spectrum Kinase Inhibitors (NSKIs) for the treatment of chronic inflammatory gastrointestinal (GI) and ocular diseases, has triggered the phase 1/2a proof of concept study in the US of TOP1630 ophthalmic solution for the treatment of the dry eye syndrome.
Verona Pharma has made an important step in the phase two clinical trial for its candidate RPL554, used for chronic obstructive pulmonary disease (COPD). Namely, the first patient has been dosed testing RPL544 as an add-on therapy to tiotropium, Spiriva.
Bayer has reported net income of €4,531 million which is 10.2% increase comparing to 2015 (€4,110 million). The company reported earnings growth in pharmaceutical activities, while other activities remain steady.
Pfizer has decided to cancel listing of its stocks from the UK listing Authority List. The company said on Wednesday it also cancels trading on the main London Stock Exchange market.
Arix Bioscience’s issued ordinary shares have on Wednesday been admitted to the Official List of the UK Listing Authority and to trading on the London Stock Exchange’s main market for listed securities under the ticker “ARIX”.
Advanced Oncotherapy, the developer of next generation proton therapy systems for cancer treatment, has secured a flexible and staged £26 million financing agreement with Bracknor Investment Group, a Dubai-based investment firm.
Players in the Global Pharmacy Repackaging Systems Market are facing tough competition. Despite tough grounds, the players such as Omnicell Inc. and Swisslog Holding AG are leading with a share of about 34% in the global market in 2015.
Bristol-Myers Squibb has entered into an ASR program with each of Morgan Stanley & Co. LLC and Goldman, Sachs & Co. to repurchase, in aggregate, $2 billion of Bristol-Myers Squibb’s common stock, and it has named three new directors.
Amgen on Tuesday got clearance from the European Commission (EC) for a new single-dose delivery option for its Repatha cardiovascular drug.
Following a diet that mimics fasting may reduce risk factors for disease in generally healthy people, according to a small study.